G
Guobang Pharma Ltd
SSE:605507
Guobang Pharma Ltd
SSE:605507
Price:
25.7
CNY
-0.46%
Market Closed
Market Cap:
¥14.4B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
G
|
Guobang Pharma Ltd
SSE:605507
|
CN |
|
Y
|
YesAsia Holdings Ltd
HKEX:2209
|
HK |
|
S
|
Siemens AG
XHAM:SIE
|
DE |
|
T
|
Tadiran Group Ltd
TASE:TDRN
|
IL |
|
Shimano Inc
F:SHM
|
JP |
|
Burnham Holdings Inc
OTC:BURCA
|
US |
|
H
|
Hershey Co
XBER:HSY
|
US |
|
F
|
Fibra Mty SAPI de CV
BMV:FMTY14
|
MX |
|
C
|
CleanTech Lithium plc
LSE:CTL
|
JE |
|
TIL Ltd
NSE:TIL
|
IN |
|
S
|
SP Plus Corp
F:PZA
|
US |
|
E
|
ESR Cayman Ltd
HKEX:1821
|
HK |
|
MPH Health Care AG
XETRA:93M1
|
DE |
|
Aluula Composites Inc
XTSX:AUUA
|
CA |
|
Blue Biofuels Inc
OTC:BIOF
|
US |
|
Tethys Oil AB
STO:TETY
|
SE |
|
C
|
Creepy Jar SA
WSE:CRJ
|
PL |
Multiples-Based Value
The Multiples-Based Value of one Guobang Pharma Ltd stock under the Base Case scenario is hidden CNY. Compared to the current market price of 25.7 CNY, Guobang Pharma Ltd is hidden .
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Guobang Pharma Ltd Multiples-Based Value
LOCKED
Multiples Across Competitors
Competitors Multiples
Guobang Pharma Ltd Competitors
Guobang Pharma Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
G
|
Guobang Pharma Ltd
SSE:605507
|
14.4B CNY | 2.4 | 16.5 | 13.8 | 13.8 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
887.6B USD | 13.6 | 43 | 29 | 31 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.2B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236.2B GBP | 5.3 | 30.6 | 16.9 | 23.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.6 | 11.6 | 13 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
300.5B USD | 4.6 | 16.5 | 10.2 | 12.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
234.4B CHF | 5.2 | 21 | 13 | 16.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.5 | 10.5 | 7.8 | 9.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.1B USD | 2.4 | 19.7 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118B USD | 2.5 | 16.7 | 7.1 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
